Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1840539 | 0.88 | CHRM1 (0.56) | CHRM1HPGDSMN1; SMN2MAPTTSHR | |
| SCHEMBL5142124 | 0.88 | HPGD (0.56) | HPGDEPHX1NPC1RAB9AABL1 | |
| SCHEMBL1840745 | 0.87 | CHRM1 (0.39) | CHRM1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1840744 | 0.85 | CHRM1 (0.47) | CHRM1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5678750 | 0.84 | CHRM1 (0.44) | CHRM1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL15241797 | 0.82 | FPR2 (0.38) | MAPTTSHR | |
| SCHEMBL16312544 | 0.81 | MAPT (0.38) | EPHX1USP2CYP1A2CYP2C9MAPT | |
| SCHEMBL5102682 | 0.80 | HDAC8 (0.39) | HPGDEPHX1CYP1A2MAPTPOLB | |
| SCHEMBL5674238 | 0.80 | CYP1A2 (0.48) | USP2CYP1A2CYP2C9TSHRCYP2C19 | |
| SCHEMBL1842789 | 0.79 | CHRM1 (0.55) | CHRM1HPGDSMN1; SMN2MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1616859-B1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU KOGYO CO LTD (JP) | 2013-09-04 | — | — | EP | claimed |
| EP-1616859-A1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | claimed |
| EP-1619189-B1 | N-(3-acyl-2-hydroxyalkyl) cycloalkyl amide derivatives | SEIKAGAKU KOGYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-1616859-B1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU KOGYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-1730125-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1008592-B1 | Cyclic amide derivatives which inhibit cathepsin K | SEIKAGAKU KOGYO CO LTD (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1619189-A1 | N-(3-acyl-2-hydroxyalkyl) cycloalkyl amide derivatives | SEIKAGAKU CORPORATION (JP) | 2006-01-25 | — | — | EP | disclosed |
| EP-1616867-A1 | Hydroxycarboxylic acid derivatives | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1616859-A1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-6117870-A | USEFUL AS THERAPEUTIC DRUG OR PREVENTIVE DRUG OF ARTHRITIS AND RHEUMATISM DUE TO INCREASE OF BONE RESORPTION IN ADDITION TO BONE DISEASES SUCH AS OSTEOPOROSIS, HYPERCALCEMIA, AND PAGET'S DISEASE | FUJIREBIO KABUSHIKI KAISHA (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1008592-A2 | Cyclic amide derivatives which inhibit cathepsin K | Fujirebio Kabushiki Kaisha (JP) | 2000-06-14 | — | — | EP | disclosed |